Publications by authors named "Zoe Goldberg"
Article Synopsis
- The study investigates the safety and effectiveness of the drug regorafenib combined with nivolumab and chemotherapy for treating advanced oesophagogastric adenocarcinoma in adults who haven't received treatment before.
- Conducted at Memorial Sloan Kettering Cancer Center, the trial included 39 patients and aimed for at least 24 to remain progression-free after 6 months to validate the treatment's potential.
- Results showed that 35 patients were evaluable for progress at 6 months, establishing a foundation for assessing the regimen's efficacy and safety in future studies.
Importance: Clonal hematopoiesis (CH) has been associated with development of atherosclerosis and leukemia and worse survival among patients with cancer; however, the association with cancer therapy efficacy, in particular immune checkpoint blockade (ICB), and toxicity has not yet been established. Given the widespread use of ICB and the critical role hematopoietic stem cell-derived lymphocytes play in mediating antitumor responses, CH may be associated with therapeutic efficacy and hematologic toxicity.
Objective: To determine the association between CH and outcomes, hematologic toxicity, and therapeutic efficacy in patients with metastatic gastrointestinal tract cancers being treated with systemic therapy, both in the first-line metastatic treatment setting and in ICB.
Article Synopsis
- The study focuses on how SARS-CoV-2 affects the quality of life related to the nose and sinuses, sense of smell, and cognitive abilities at various stages of infection.
- *Olfactory dysfunction is common in COVID-19 patients, and while the sense of smell may improve over time, cognitive issues, particularly in processing speed, persist even after recovery.
- *The results indicate that recovered patients scored lower in smell tests compared to those actively infected or healthy controls, highlighting that olfactory and cognitive impacts from the virus can vary significantly.
Background: Patients with germline/somatic BRCA1/BRCA2 mutations (g/sBRCA1/2) comprise a distinct biologic subgroup of pancreas ductal adenocarcinoma (PDAC).
Methods: Institutional databases were queried to identify patients who had PDAC with g/sBRCA1/2. Demographics, clinicopathologic details, genomic data (annotation sBRCA1/2 according to a precision oncology knowledge base for somatic mutations), zygosity, and outcomes were abstracted.
A 64-year-old man with anal cancer underwent follow-up F-FDG PET/CT to evaluate chemoradiation therapy response 5 months after an initial PET/CT. The follow-up F-FDG PET/CT demonstrated new FDG-avid curvilinear soft tissue adjacent to the abdominal aorta, interpreted as an aortic dissection. Despite lack of clinical symptoms, the patient was directed to an emergency room the same day, where a contrast-enhanced CT confirmed an aortic aneurysm with dissection.
View Article and Find Full Text PDFBackground: Angiogenesis is critical to gastroesophageal adenocarcinoma growth and metastasis. Regorafenib is a multikinase inhibitor targeting angiogenic and stromal receptor tyrosine kinases. We evaluated whether regorafenib augments the antitumor effect of first-line chemotherapy in metastatic esophagogastric cancer.
View Article and Find Full Text PDFPurpose: VEGFR2-directed therapy is commonly used to treat metastatic esophagogastric cancer, but disease progresses in most patients within months. Therapeutic resistance is likely mediated in part by co-occurring amplifications of the genes for multiple oncogenic receptor tyrosine kinases (RTK). We therefore tested the efficacy of combined inhibition of VEGFR1-3, PDGFα/β, and FGFR1-3 using nintedanib.
View Article and Find Full Text PDFWomen with substance use disorders (SUDs) often experience inadequate health care, mental and physical health problems, trauma, lack of social support, and undermining of support for psychological needs of autonomy, competence, and relatedness needed for motivation and well-being. For women with SUD trying to reclaim sobriety and a healthy life, family can present both barriers and support. The aim of this study is to gain a deeper understanding of the intersection of family relationships with motivation of women in Drug Treatment Court (DTC) to attain their health goals.
View Article and Find Full Text PDFBackground: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma; however, there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examined the efficacy and safety of modified docetaxel, cisplatin and 5 fluorouracil (mDCF) plus trastuzumab in a single-arm multicenter phase II trial.
Methods: Previously untreated patients with HER2-positive metastatic gastric or GE junction adenocarcinoma were treated with mDCF and trastuzumab every 2 weeks.